89 related articles for article (PubMed ID: 27103124)
41. An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects.
Im YJ; Jeon JY; Kim EY; Kim Y; Oh DJ; Yoo JS; Shin DH; Chae SW; Kim MG
Clin Ther; 2015 Feb; 37(2):376-89. PubMed ID: 25618318
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic Studies in Healthy Subjects for the Development of an Extended-Release Tablet Formulation of Guaifenesin: A 505(b)(2) New Drug Application Approval.
Vilson L; Owen JS
Clin Pharmacol Drug Dev; 2013 Jan; 2(1):25-32. PubMed ID: 27121557
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.
Lucchi M; Damle B; Fang A; de Caprariis PJ; Mussi A; Sanchez SP; Pasqualetti G; Del Tacca M
J Antimicrob Chemother; 2008 Apr; 61(4):884-91. PubMed ID: 18252692
[TBL] [Abstract][Full Text] [Related]
44. Detection of capecitabine (Xeloda®) on the skin surface after oral administration.
Huang MD; Fuss H; Lademann J; Florek S; Patzelt A; Meinke MC; Jung S
J Biomed Opt; 2016 Apr; 21(4):47002. PubMed ID: 27117193
[TBL] [Abstract][Full Text] [Related]
45. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
46. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
[TBL] [Abstract][Full Text] [Related]
47. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.
Morton T; Kostenbader K; Montgomery J; Devarakonda K; Barrett T; Webster L
Postgrad Med; 2014 Jul; 126(4):20-32. PubMed ID: 25141240
[TBL] [Abstract][Full Text] [Related]
48. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
49. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
50. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
Kim KA; Park SJ; Kim C; Park JY
Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
[TBL] [Abstract][Full Text] [Related]
51. Novel microbially triggered colon specific delivery system of 5-Fluorouracil: statistical optimization, in vitro, in vivo, cytotoxic and stability assessment.
Dev RK; Bali V; Pathak K
Int J Pharm; 2011 Jun; 411(1-2):142-51. PubMed ID: 21463667
[TBL] [Abstract][Full Text] [Related]
52. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations.
Leppik IE; Hovinga CA
Epilepsia; 2013 Jan; 54(1):28-35. PubMed ID: 23190215
[TBL] [Abstract][Full Text] [Related]
53. The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets.
Mohamed FA; Roberts M; Seton L; Ford JL; Levina M; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2013 Aug; 39(8):1167-74. PubMed ID: 22540355
[TBL] [Abstract][Full Text] [Related]
54. Effect of protein release rates from tablet formulations on the immune response after sublingual immunization.
Borde A; Ekman A; Holmgren J; Larsson A
Eur J Pharm Sci; 2012 Nov; 47(4):695-700. PubMed ID: 22959953
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration.
Sista S; Lai JC; Eradiri O; Albert KS
J Clin Pharmacol; 2003 Oct; 43(10):1149-57. PubMed ID: 14517197
[TBL] [Abstract][Full Text] [Related]
56. Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs.
Koryakova A; Shcherbakova V; Riabova O; Kazaishvili Y; Bolgarin R; Makarov V
Microbiol Spectr; 2023 Feb; 11(1):e0232722. PubMed ID: 36507624
[TBL] [Abstract][Full Text] [Related]
57. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Menon R; Tolbert D; Cefali E
Biopharm Drug Dispos; 2007 Sep; 28(6):297-306. PubMed ID: 17571283
[TBL] [Abstract][Full Text] [Related]
58. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.
Stark JG; Engelking D; McMahen R; Sikes C
Postgrad Med; 2016 Sep; 128(7):648-55. PubMed ID: 27488574
[TBL] [Abstract][Full Text] [Related]
59. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
